

A role for microRNA-155 in the control of infection

**By
Victoria Francis John**

2010



**This dissertation is submitted for the degree of Doctor
of Philosophy**

**Trinity Hall
University of Cambridge**

Abstract

MicroRNAs (miRNAs) are small (~22 nucleotide) non-coding regulatory RNA molecules which influence the expression of genes within eukaryotic cells. miRNAs function through targeted binding to the 3' un-translated region (UTR) of messenger RNAs (mRNAs) in a sequence specific manner. Recent studies have implicated microRNA-155 (miR-155) as an important player in the development and function of a number of immune cells including B and T cells, macrophages and dendritic cells. The aim of this study was to investigate the role of miR-155 in controlling either a mucosal *Citrobacter rodentium* or a systemic *Salmonella enterica* serovar Typhimurium infection in the context of the overall immune response. Here we present evidence that miR-155-deficient mice are less competent in their ability to eradicate a mucosal *C. rodentium* infection compared with wild type control C57BL/6 mice. We show that miR-155-deficient mice have a higher *C. rodentium* burden in gastrointestinal tissue and also exhibit spread into systemic tissues. Additionally, we demonstrate that germinal centre formation and humoral immune responses are impaired in the absence of miR-155. In view of the fact that this phenotype is largely reproduced in μ MT (B cell-deficient) mice reconstituted with miR-155-deficient B cells we conclude that miR-155 is required to control *C. rodentium* infection. Further, miR-155-deficient mice were able to clear a primary infection with an attenuated strain of *S. Typhimurium* but were defective in their immune response to *Salmonella*.

Acknowledgements

First and foremost, I would like to say a massive THANKS to my family, especially Mum, Dad, Russ and Aled, for endlessly listening to me, encouraging me and for not letting me give up. Without their eternal support I definitely would not have made it this far.

I would like to thank Professor Gordon Dougan for allowing me to complete my PhD in his laboratory and for all his expert help and guidance.

Thank you to members of Team 15 and ex-Team 100, particularly Sally, Fernanda, Dave and Del for cheering me up every day.

A special thanks to Cordy for all her amazing help and the many stress-relieving shopping trips and also thanks to Amy and Zahra for all the tea, chats and cupcakes.

Finally I'd like to say a huge thanks to Gemma Langridge with whom I started my PhD. She has helped me enormously throughout the last four years and has been a truly fabulous friend.

Declaration

I hereby declare that this dissertation is the result of my own work and contains no material written by any other person. It includes nothing that is the outcome of work done in collaboration except where specifically indicated here or in the Materials and Methods section. I was fully involved in all aspects of the design and the experimental work presented.

Dr S Clare (Wellcome Trust Sanger Institute, Hinxton, Cambridge), assisted the author in performing tissue collection from experimental animals and performed immunisations and animal procedures during the studies.

David Goulding (Wellcome Trust Sanger Institute, Hinxton, Cambridge) performed the Scanning Electron and Transmission Electron Microscopy in assistance with the author.

Following RNA extraction, transcript analysis was performed by the Microarray Facility at the Wellcome Trust Sanger Institute, Cambridge. In addition, microarray data analysis was conducted by Cei Abreu-Goodger (European Bioinformatics Institute, Hinxton, Cambridge).

Dr Elena Vigorito (Babraham Institute, Cambridge) created all chimeric mice used throughout this study.

None of the material presented herein has been submitted previously for the purpose of obtaining another degree. I confirm that this thesis does not exceed 300 single-sided pages of double spaced text, or 60,000 words.

Victoria F. John

October, 2010

Contents

Abstract.....	2
Acknowledgements	3
Declaration.....	4
Contents	5
List of Figures.....	13
List of Tables	17
List of Printed Supplementary Figures and Tables	18
Abbreviations.....	20
1 Introduction	26
1.1 MicroRNAs.....	26
1.1.1 Discovery.....	26
1.1.2 MicroRNAs post-transcriptionally regulate gene expression....	26
1.2 miR-155/ B cell integration cluster (BIC)	28
1.2.1 Identification of miR-155	28
1.2.2 miR-155 as an oncogenic microRNA.....	29
1.2.3 miR-155 is important for normal immune function	29
1.2.3.1 The role of miR-155 in innate immunity	29
1.2.3.2 miR-155 function in T cells	30

1.2.3.3	The miR-155-deficient mouse	31
1.2.3.4	miR-155 is required for normal B cell function and germinal centre formation.....	32
1.3	The immune system and infection control.....	35
1.3.1	The innate immune system	35
1.3.2	The adaptive immune system	36
1.3.2.1	T lymphocytes.....	36
1.3.2.2	B lymphocytes	40
1.3.2.2.1	B cell activation.....	46
1.3.2.2.2	Germinal centres	50
1.3.2.2.3	Antibody Affinity maturation.....	53
1.3.3	Lymphoid tissue and the Mucosal immune system.....	55
1.3.3.1	Follicle-associated epithelium (FAE)	57
1.3.3.2	Mucosal immune system.....	59
1.4	<i>Citrobacter rodentium</i>	61
1.4.1	History	61
1.4.2	Attaching-Effacing enteric bacterial pathogens	61
1.4.3	Attaching and Effacing (A/E) lesion formation	62
1.4.4	<i>C. rodentium</i> infection in mice	64
1.4.5	Immune response to <i>C. rodentium</i>	64

1.5	<i>S. Typhimurium</i>	69
1.5.1	<i>S. Typhimurium</i> infection in mice	69
1.5.2	The innate immune response to <i>S. Typhimurium</i>	73
1.5.3	The adaptive immune response to <i>S. Typhimurium</i>	75
1.5.3.1	Role of T cells during the immune response against <i>S. Typhimurium</i>	75
1.5.3.2	Role of B cells during the immune response against <i>S. Typhimurium</i>	77
1.6	Hypothesis.....	79
1.7	Aims of this thesis.....	79
2	Materials and methods	80
2.1	Materials	80
2.1.1	Reagents.....	80
2.1.2	Bacterial strains	80
2.1.3	Immunofluorescence antibodies	80
2.1.4	ELISA antibodies	81
2.1.5	Mice	81
2.1.5.1	Chimeric mice	81
2.2	Methods.....	82
2.2.1	Bacterial growth conditions.....	82

2.2.2	Animal methods.....	82
2.2.2.1	Preparation of inoculum.....	82
2.2.2.1.1	Oral <i>C. rodentium</i>	82
2.2.2.1.2	Intravenous <i>S. Typhimurium</i> SL3261	82
2.2.2.1.3	Intravenous <i>S. Typhimurium</i> SL1344	83
2.2.2.1.4	Oral <i>S. Typhimurium</i> C5	83
2.2.2.2	Determination of number of viable <i>C. rodentium</i> in faecal samples	83
2.2.2.3	Determination of pathogen burden in tissues.....	84
2.2.3	Molecular methods	84
2.2.3.1	Total RNA and miRNA extraction	84
2.2.3.2	RNA/miRNA quantification and quality control	85
2.2.3.3	Microarray.....	85
2.2.3.4	Analysis and annotation of microarray data	86
2.2.3.5	Quantitative, Real-Time PCR (RT-PCR) for RNA	87
2.2.3.5.1	Reverse-Transcription of total RNA	87
2.2.3.5.2	Real-Time PCR step.....	89
2.2.3.5.2.1	QuantiTect Primers.....	90
2.2.3.6	Quantitative, RT- PCR for miRNA	92
2.2.3.6.1	Reverse-Transcription Step	92

2.2.3.6.2	Real-Time PCR for Detection of miRNA or Noncoding RNA	93
2.2.3.6.2.1	miScript Primer Assay.....	95
2.2.4	ELISA methods	95
2.2.4.1	Serum extraction	95
2.2.4.2	ELISA for total Ig, IgG, IgG1, IgG2a, IgA and IgM in mouse sera (General ELISA protocol).....	95
2.2.4.3	ELISA for IgA in faecal samples.....	96
2.2.5	Tissue staining methods.....	97
2.2.5.1	Paraffin embedding tissue and sectioning.....	97
2.2.5.1.1	Histology	97
2.2.5.2	General Chemical Fixation and fine preservation for Transmission Electron Microscopy (TEM).....	98
2.2.5.3	Scanning Electron Microscopy	99
2.2.5.4	Frozen sectioning	99
2.2.5.4.1	Immunofluorescent staining of frozen tissue sections .	100
2.3	Statistical analysis	100
3	Immune response to <i>C. rodentium</i> in miR-155-deficient mice	101
3.1	Introduction.....	101
3.2	Results.....	101

3.2.1	miR-155 expression in C57BL/6 mice following infection with <i>C. rodentium</i>	101
3.2.2	Prolonged clearance of <i>C. rodentium</i> infection in miR-155-deficient mice.....	104
3.2.3	Increased <i>C. rodentium</i> pathogen burden in gastrointestinal tissues of miR-155-deficient mice	106
3.2.4	miR-155-deficient mice develop more severe pathological changes in the colonic mucosa	109
3.2.5	Deficiency of miR-155 leads to the development of polymicrobial infections and severe damage to the colonic mucosa.....	112
3.2.6	Systemic spread of <i>C. rodentium</i> in miR-155-deficient mice	117
3.2.7	miR-155-deficient mice mount a blunted humoral immune responses to <i>C. rodentium</i>	119
3.2.8	Germinal centre formation is adversely affected in infected miR-155-deficient mice	123
3.2.9	Genome-wide analysis of gene expression in <i>C. rodentium</i> infected tissues.....	127
3.2.9.1	Transcriptional profiling of <i>C. rodentium</i> -infected ceecal patches reveals that B cell function is affected in the absence of miR-155, on day 4 pi	129
3.2.9.2	Loss of miR-155 results in the up-regulation of genes involved in metabolism, catabolism and biosynthesis.....	132

3.2.9.3	Chemokine (C-X-C motif) receptor 3 (CXCR3) is down-regulated in miR-155-deficient caecal patches 14 days after infection with <i>C. rodentium</i>	135
3.2.9.4	Global gene expression analysis of the colonic response to <i>C. rodentium</i> in miR-155-deficient mice reveals only minor differences, despite gross pathological changes	137
3.3	Phenotype is recapitulated in miR-155-deficient, μ MT-deficient chimeric mice.....	139
3.3.1	miR-155-deficient, μ MT-deficient chimeras take significantly longer to resolve infection with <i>C. rodentium</i>	139
3.3.2	miR-155-deficient, μ MT-deficient chimeras are highly susceptible to <i>C. rodentium</i> infection	141
3.3.3	Absence of miR-155 leads to impaired production of <i>C. rodentium</i> -specific antibody	144
3.3.4	Impaired germinal centre formation is B cell intrinsic.....	146
3.4	Discussion	148
4	Immune response to <i>S. Typhimurium</i> in miR-155-deficient mice	152
4.1	General introduction	152
4.2	Results.....	153
4.2.1	Infection with virulent <i>S. Typhimurium</i> strain SL1344	153
4.2.2	miR-155 is not required for the formation of pathological lesions at infection foci during infection with virulent <i>S. Typhimurium</i>	155

4.2.3	miR-155 not essential to resolve infection with attenuated <i>S.</i> <i>Typhimurium</i>	158
4.3	Chimeras with miR-155-deficient B cells have impaired humoral immune responses following vaccination.....	160
4.3.1	Immunised miR-155-deficient, μ MT-deficient mice are less readily protected when challenged with virulent <i>Salmonella</i>	164
4.4	Discussion	166
5	Final discussion.....	168
	References	174
	Supplementary Figures and Tables.....	191
	List of Supplementary Figures and Tables	212
	CD of Supplementary Figures and Tables	Back Page

List of Figures

Figure 1. A Model for Human RISC Function Involving miRNA and siRNA	27
Figure 2. Gene targeting strategy to generate bic/miR-155-deficient mice	31
Figure 3. miR-155 ^{-/-} mice show impaired T cell-dependent antibody responses.....	33
Figure 4. Antigen presentation between a professional APC and naive CD4 ⁺ T cell	38
Figure 5. Effector functions of Th1 and Th2 subsets of CD4 helper T lymphocytes.....	40
Figure 6. General structure of an antibody molecule	41
Figure 7. Immunoglobulin Somatic Recombination	42
Figure 8. Stages in B cell development	45
Figure 9. B cell antigen receptor signal transduction cascade.....	47
Figure 10. Th cell-regulated B cell memory development.....	48
Figure 11. B cell transmembrane receptors and T cell ligands involved in contact-dependent regulation of B cell activation ⁷²	49
Figure 12. Schematic representation of germinal centre compartments.....	51
Figure 13. Two models of GC B cell Selection within the GC	52
Figure 14. Processing the AID-induced U•G mismatches during SHM (left) and CSR (right).....	54
Figure 15. Gastric-associated lymphoid tissue (GALT).....	56

Figure 16. M cell	58
Figure 17. Function of GALT.....	59
Figure 18. 'Attaching and Effacing' (A/E) lesions	62
Figure 19. A model of EPEC interaction with epithelial cells	63
Figure 20. <i>C. rodentium</i> counts in mice depleted of CD4+ or CD8+ T cells..	65
Figure 21. <i>C. rodentium</i> counts in μ MT and control C57BL/6 mice.	66
Figure 22. <i>C. rodentium</i> -induced colitis in LT β ^{-/-} and LT β R ^{-/-} mice	67
Figure 23. Manipulation of the mouse host effect sterilising immunity, other antibacterial pathways and pathology ¹⁶¹	68
Figure 24. <i>S. Typhimurium</i> infection in mice	70
Figure 25. Pathogenesis of <i>S. Typhimurium</i> in mice	72
Figure 26. The immune response to <i>Salmonella</i>	75
Figure 27. Igh-6 ^{-/-} (B cell deficient) mice fail to mount solid acquired resistance to oral challenge with virulent <i>Salmonella Typhimurium</i>	78
Figure 28. Expression of <i>miR-155</i> gene in C57BL/6 mice infected with <i>C.</i> <i>rodentium</i>	103
Figure 29. Colonisation and clearance of <i>C. rodentium</i> in miR-155-deficient and C57BL/6 mice.....	105
Figure 30. <i>C. rodentium</i> burden in gastrointestinal tissues of C57BL/6 and miR-155-deficient mice on day 4 and 14 pi.	107
Figure 31. <i>C. rodentium</i> burden in gastrointestinal tissues of C57BL/6 and miR-155-deficient mice on day 20 and 26 pi	108

Figure 32. Histopathological analysis of infected colons from miR-155-deficient and control C57BL/6 mice	111
Figure 33. Histopathology in the distal colon of infected C57BL/6 and miR-155 ^{-/-} mice	113
Figure 34. Polymicrobial infection in miR-155-deficient mice infected with <i>C. rodentium</i>	115
Figure 35. miR-155-deficient mice exhibit systemic spread of <i>C. rodentium</i>	118
Figure 36. Humoral immune responses to <i>C. rodentium</i> surface protein EspA	121
Figure 37. Faecal IgA responses to <i>C. rodentium</i> surface protein EspA.....	122
Figure 38. Germinal centre formation in C57BL/6 and miR-155-deficient mice following infection with <i>C. rodentium</i>	124
Figure 39. Presence of tingible body macrophages in the caecal patches of C57BL/6 and miR-155-deficient mice 14 days after infection with <i>C. rodentium</i>	126
Figure 40. Genome-wide analysis of gene expression in <i>C. rodentium</i> infected tissues.....	131
Figure 41. Colonisation and clearance of <i>C. rodentium</i> in miR-155-deficient, μ MT-deficient and wild-type, μ MT-deficient chimeric mice	140
Figure 42. CFU of <i>C. rodentium</i> in gastrointestinal tissues of miR-155-deficient, μ MT-deficient and control wild-type, μ MT-deficient chimeras ...	142
Figure 43. CFU of <i>C. rodentium</i> in systemic tissues of miR-155-deficient, μ MT-deficient and control wild-type, μ MT-deficient chimeras	143

Figure 44. Humoral immune responses to <i>C. rodentium</i> surface protein EspA in miR-155-deficient, μ MT-deficient and wild-type, μ MT-deficient mice...	145
Figure 45. Germinal centre formation in miR-155-deficient, μ MT-deficient and control wild-type, μ MT-deficient mice, following infection with <i>C. rodentium</i>	147
Figure 46. CFU of <i>S. Typhimurium</i> SL1344 in systemic tissues of miR-155-deficient and C57BL/6 mice	154
Figure 47. Granuloma formation in miR-155-deficient and C57BL/6 mice following infection with <i>S. Typhimurium</i> SL1344	157
Figure 48. CFU of <i>S. Typhimurium</i> SL3261 in systemic tissue from miR-155-deficient and C57BL/6 mice	159
Figure 49. CFU of <i>S. Typhimurium</i> SL3261 in systemic tissue from miR-155-deficient, μ MT-deficient and wild-type, μ MT-deficient mice at day 20 pi...	161
Figure 50. TetC-specific Ig levels from miR-155-deficient, μ MT-deficient and wild-type, μ MT-deficient chimeras infected with attenuated <i>Salmonella</i> , 21 days after infection	162
Figure 51. TetC-specific Ig levels from miR-155-deficient, μ MT-deficient and wild-type, μ MT-deficient chimeras infected with attenuated <i>Salmonella</i> , 56 days after infection	163
Figure 52. Survival of immunised mice challenged with virulent <i>S. Typhimurium</i>	165
CD of Supplementary Figures and Tables	Back Page

List of Tables

Table 1. Bacterial strains used during study.....	80
Table 2. Antibodies for immunofluorescence staining.....	80
Table 3. Antibodies Used for ELISAs.....	81
Table 4. Genomic DNA (gDNA) elimination reaction components.....	88
Table 5. Reverse-transcription reaction components.....	88
Table 6. Reverse-transcription reaction components.....	89
Table 7. Cycling conditions for two-step RT-PCR.....	90
Table 8. Quantitect Primers.....	91
Table 9. Reverse-transcription reaction components for miRNA or Non-coding RNA.....	93
Table 10. Reaction setup for RT-PCR detection of miRNA and noncoding RNA.....	94
Table 11. Cycling conditions for real-time PCR using block cyclers.....	94
Table 12. miScript primer Assay.....	95
Table 13. GO conditional test for over-representation of genes up-regulated in miR-155-deficient caecal patches, 4 days after infection.....	134
CD of Supplementary Figures and Tables.....	Back Page

List of Printed Supplementary Figures and Tables

Figure S 1. The B cell Receptor signalling pathway is downregulated in the caecal patch of miR-155-deficient mice on day 4 pi	191
Figure S 2. Sylamer analysis	193
Table S 5. Gene to KEGG test for over-representation within upregulated mRNAs in miR-155-deficient caecal patch on day 4 pi	194
Table S 6. Gene to KEGG test for over-representation within downregulated mRNAs in miR-155-deficient caecal patch on day 4 pi	195
Table S 7. Gene to GO-BP conditional test for over-representation within mRNAs upregulated in miR-155-deficient caecal patch on day 4 pi	196
Table S 8. Gene to GO-BP conditional test for over-representation within mRNAs downregulated in miR-155-deficient caecal patch on day 4 pi	198
Table S 14. Gene to KEGG test for over-representation within mRNAs upregulated in miR-155-deficient caecal patch on day 14 pi	199
Table S 15. Gene to KEGG test for over-representation within mRNAs downregulated in miR-155-deficient caecal patch on day14 pi	200
Table S 16. Gene to GO-BP conditional test for over-representation within mRNAs upregulated in miR-155-deficient caecal patch on day14 pi	201
Table S 17. Gene to GO-BP conditional test for over-representation within downregulated mRNAs in miR-155-deficient caecal patch on day 14 pi	202
Table S 23. Gene to KEGG test for over-representation within mRNAs upregulated in miR-155-deficient colon on day4 pi	203

Table S 24. Gene to KEGG test for over-representation within mRNAs downregulated in miR-155-deficient colon on day4 pi	204
Table S 25. Gene to GO-BP conditional test for over-representation within mRNAs upregulated in miR-155-deficient colon on day4 pi.....	205
Table S 26. Gene to GO-BP conditional test for over-representation within mRNAs downregulated in miR-155-deficient colon on day 4 pi	206
Table S 32. Gene to KEGG test for over-representation within mRNAs upregulated in miR-155-deficient colon on day14 pi.....	207
Table S 33. Gene to KEGG test for over-representation within mRNAs downregulated in miR-155-deficient colon on day14 pi	208
Table S 34. Gene to GO-BP conditional test for over-representation within mRNAs upregulated in miR-155-deficient colon on day14 pi.....	209
Table S 35. Gene to GO-BP conditional test for over-representation within mRNAs downregulated in miR-155-deficient colon on day14 pi.....	211

Abbreviations

ADCC	Antibody-dependent cell-mediated cytotoxicity
A/E lesion	Attaching and effacing lesion
AICDA	Activation-induced cytidine deaminase
ALV	Avian leukosis virus
AP	Activator protein
APCs	Antigen presenting cells
BALT	Bronchus-associated lymphoid tissue
BCR	B-cell receptor
Bfp	Bundle forming pili
BIC	B-cell integration cluster
BL	Burkitt lymphoma
BSA	Bovine serum albumin
CFU	Colony forming units
CGG	Chicken gamma globulin
CSR	Class switch recombination
CTLs	Cytotoxic T-lymphocytes
CXCR	Chemokine, CXC Motif, Receptor
DC	Dendritic cell
D-PBS	Dulbecco's phosphate buffered saline

DNP	Dinitrophenylated
EHEC	Enterohaemorrhagic <i>Escherichia Coli</i>
ELISA	Enzyme-linked immunosorbant assay
EPEC	Enteropathogenic <i>Escherichia Coli</i>
ESP	Expressed surface protein
EST	Expressed sequence tag
FAE	Follicle associated epithelium
FasL	Fas Ligand
FDC	Follicular dendritic cell
GA	Glutaraldehyde
GALT	Gastric-associated lymphoid tissue
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GC	Germinal centre
gDNA	Genomic DNA
GO	Gene ontology
HEV	High endothelial venule
HL	Hodgkin lymphoma
HRP	Horse radish peroxidase
HUL	Haemolytic uraemic syndrome
IBD	Inflammatory bowel disease

ICAM	Intracellular adhesion molecule
IFN	Interferon
Ig	Immunoglobulin
IHC	Immunohistochemistry
IL	Interleukin
ILF	Isolated lymphoid follicle
INOS	Inducible nitric oxide synthase
ITAM	Immunoreceptor tyrosine activation motif
i.v.	Intravenous
KEGG	Kyoto Encyclopedia of Genes and Genomes
KDa	Kilo Dalton
KLH	Keyhole limpet hemocyanin
LB	Luria Bertani
LEE	Locus of enterocyte effacement
LPS	Lipopolysaccharide
LT	Lymphotoxin
MALT	Mucosal-associated lymphoid tissue
M cell	Microfold cell
MHC	Major histocompatibility complex
miRNA	microRNA

mLN	Mesenteric lymph node
MMP	Matrix metalloproteinase
MMR	Mismatch repair
MPEC	Murine-pathogenic <i>Escherichia Coli</i>
mRNA	messenger RNA
Myd88	Myeloid differentiation factor 88
M ϕ	Macrophage
μ MT mice	B cell-deficient mice
NALT	Nasal-associated lymphoid tissue
NEO	Neomycin
NF	Nuclear factor
NFAT	Nuclear factor of activated cells
NHL	Non-Hodgkin lymphoma
NK	Natural Killer cell
NP	3-hydroxy-4-nitro-phenylacetyl
OPD	O-Phenylenediamine dihydrochloride
ORF	Open reading frame
PAMPs	Pathogen associated molecular patterns
PBS	Phosphate buffered saline
PFA	Paraformaldehyde

pi	Post-inoculation
pIgR	Polymeric immunoglobulin receptor
PNA	Peanut agglutinin
PO	Propylene oxide
Pol	Polymerase
PP	Peyer's patch
RAG	Recombination activating gene
RISC	RNA-induced silencing complex
PKC	Protein kinase C
rpm	Revolutions per minute
PRRs	Pattern recognition receptors
RSS	Recombination signal sequences
RT	Room temperature
RNIs	Reactive nitrogen intermediates
RT-PCR	Reverse transcription-polymerase chain reaction
SCs	Stromal cells
SEM	Standard error mean
SHM	Somatic hypermutation
STAT	Signalling transducer and activator of transcription
TBMs	Tingible body macrophages

TCR	T-cell receptor
TdT	Terminal deoxynucleotidyl transferase
TetC	Tetanus toxin fragment C
T _H	T helper
TIR	Translocated intimin receptor
TLR	Toll-like receptor
TMCH	Transmissible murine colonic hyperplasia
TNF	Tumour necrosis factor
Tween	Polyoxyethylene-sorbitan monolaurate
T3SS	Type 3 Secretion System
UTR	Untranslated region